Roche Holding AG (RHHBY) - What Are Brokerages Thinking About This Stock?

Key Points

• Roche Holding AG has a “Moderate Buy” consensus rating from 12 analysts, evenly split between six buy ratings and six holds. The average 12-month price target is $60.00, above the stock’s reported opening price of $54.10.
• Recent analyst actions were mixed but included bullish moves: Morgan Stanley upgraded Roche to “overweight” with a $63 target, while Royal Bank of Canada initiated coverage with an “outperform” rating.
• Several institutional investors increased or initiated positions in Roche, while the stock traded between $40.07 and $60.85 over the past year. The company operates across pharmaceutical and diagnostics businesses, with major focus areas including oncology, immunology and rare diseases.

Shares of Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $60.00.

A number of brokerages have weighed in on RHHBY. HSBC reissued a "hold" rating on shares of Roche in a research note on Thursday, September 10th. Zacks Research raised Roche from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Morgan Stanley upgraded Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 target price for the company in a research note on Friday, August 7th. Finally, Royal Bank Of Canada began coverage on Roche in a research report on Tuesday, September 8th. They set an "outperform" rating on the stock.

Hedge Funds Weigh In On Roche

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Roche by 15.3% during the 3rd quarter. GAMMA Investing LLC now owns 33,458 shares of the company's stock worth $1,736,000 after buying an additional 4,443 shares during the last quarter. Renasant Bank acquired a new stake in Roche during the 2nd quarter worth approximately $210,000. North Star Asset Management Inc. purchased a new position in Roche in the second quarter valued at approximately $1,351,000. Puzo Michael J purchased a new position in shares of Roche in the 2nd quarter valued at $1,229,000. Finally, Fulton Bank N.A. raised its position in Roche by 5.1% in the second quarter. Fulton Bank N.A. now owns 11,572 shares of the company's stock valued at $597,000 after purchasing an additional 559 shares during the period.

Roche Price Performance

RHHBY stock opened at $54.10 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.69. Roche has a one year low of $40.07 and a one year high of $60.85. The company has a 50 day moving average price of $54.90 and a two-hundred day moving average price of $52.59.

Roche Company Profile

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche's pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.